Misato Bosma-Miyamasu

Misato Bosma-Miyamasu has a long and varied work experience. Misato began their career in 2006 as a Patent Translator / Translation Checker for Pacific International Translations NZ Ltd & Flamingo Language Services in Auckland, New Zealand. In 2007, they moved to Neuren Pharmaceuticals Limited as a Research Scientist. From 2008 to 2021, they held various roles including Director / Principal Scientist at The Australian Tissue Engineering Centre (ATEC), Honorary appointment as a Fellow at the University of Melbourne, Strategy Consultant at Compass Pro Bono, Head of Global MDx Technology Office North America and Team Leader, New Product Development at QIAGEN, Director, Products Innovation and Strategy and Program Manager, Product Development, ACESO at The Henry M. Jackson Foundation for the Advancement of Military Medicine, Advisory Board Member, PFACQS at MedStar Health, and Director of Corporate Partnerships, Johns Hopkins Technology Ventures (JHTV) at The Johns Hopkins University. Currently, they are the Senior Director, Business Development & Alliance Management at F2G, a clinical-stage biopharmaceutical company focused on development of novel therapies / new class of molecules to treat life-threatening invasive fungal infections.

Misato Bosma-Miyamasu received their Doctor of Philosophy (PhD) in Immunology and Pharmaceutical Sciences from The University of Tokyo. Misato then earned their Bachelor of Pharmaceutical Sciences from Kitasato University. After completing their undergraduate degree, they went on to pursue a Post-Doctoral in Immunology, Disease Biology, and Cell Biology from the Japan Society for the Promotion of Science.